Climate tech companies are going public. What’s next?

This year, there’s been a wave of notable energy companies going public via IPO in the US.

The solar and battery company Solv Energy went public in February, to the tune of $6 billion. X-energy, which is building small modular nuclear reactors, did the same in April, and its stocks surged on its first day of trading to hit a $11.5 billion market cap. Most recently, the geothermal company Fervo Energy went public in mid-May, and its market cap is now about $12.4 billion.

Those are all success stories in the IPO world. And it certainly doesn’t feel like a coincidence that all these companies are racing to provide electricity in an era of rising demand (partly due to data centers). Let’s take a look at how these firms are doing, what this moment says about the grid, and what’s coming next. 

Let’s start with Fervo Energy, a company we’ve covered a lot over the years that’s working to develop enhanced geothermal energy. (We included it on our 2025 list of Climate Tech Companies to Watch.) While conventional geothermal requires finding specific spots with hot rock, water, and fractures to support a power plant, Fervo essentially uses fracking techniques to create the necessary conditions.

The company was founded in 2017, and it raised about $1.5 billion from investors over the years before its IPO.

Fervo’s first commercial project, Cape Station in Utah, is expected to have a capacity of about 500 megawatts. The first unit is set to start generating power for customers by October and the next two units by January 2027.

The new funding from the IPO could help the company scale. Fervo currently has over 600 megawatts’ worth of binding power purchase agreements. And it has leases for land that could together generate more than 40 gigawatts of electricity. (As of 2024, the entire US geothermal fleet had a capacity of just 4 gigawatts.)

The company also has an eye on cutting construction and drilling costs—its Cape Station plant is expected to cost about $7 per kilowatt, which is cheaper than new nuclear power plants but over twice the expense of building a new natural-gas plant in the US. 

X-energy also aims to provide reliable clean power: it’s part of the wave of next-generation nuclear companies working on small modular reactors. The company is building high-temperature gas-cooled reactors, which flow helium over self-contained pebbles of nuclear fuel. These reactors will each generate 80 megawatts of electricity, less than one-tenth the output of larger ones like Unit 4 at Plant Vogtle in Georgia, the most recent addition to the commercial nuclear fleet in the US.  

X-energy also saw its IPO go well, and prices surged in trading after the initial offering. One interesting tidbit here—the company had previously planned to go public in 2023 but decided against it because of difficult market conditions.

The company is still years away from demonstrating its technology in a commercial project. 

You may recall a story I wrote last year about its effort to build nuclear reactors at the site of a Dow Chemical plant in Texas. The company recently received a key environmental approval for that project, though it’s still waiting for the final green light from the Nuclear Regulatory Commission to start construction.

Finally, Solv Energy builds solar and energy storage projects, mostly for utilities and independent power producers. Solar and batteries are some of the cheapest and easiest technologies to add to the grid, so this one could get a lot of capacity online, quickly. The company already has 21 gigawatts’ worth of projects operational across 35 states.

Many companies in the energy sector are pinning their hopes on the rapid growth in data center construction and operation. The AI boom has transformed the energy landscape, pushing electricity demand higher in a country where it’s been relatively flat for the last decade or so. Solv Energy mentioned data centers over a dozen times in documents filed with the Securities and Exchange Commission before its IPO. 

And Fervo and X-energy are particularly connected to the tech giants driving AI. Google has been a longtime investor in Fervo and also pioneered what it calls its clean transition tariff with the company. Amazon is a client of X-energy as well as an investor; it reportedly owns close to 20% of the company.

Fervo and X-energy are also in industries that occupy a political sweet spot. President Trump and his administration have gone after wind power and other renewables, cutting off existing support and slowing approvals for new projects. Meanwhile, geothermal and particularly nuclear power have kept favor with the federal government and enjoyed continued tax credits and grant funding.

If a few big leaders cash through these IPOs, it could help investors feel more confident about supporting the energy sector, even if that money is concentrated in later-stage ventures like these rather than earlier-stage companies. 

We could see other firms, particularly in nuclear and geothermal, attempt a similar route in the year ahead.

A key thing to watch here will be whether Fervo and X-energy in particular can succeed in scaling up and deploying their technology. If either of these companies stumbles or misses a timeline, it could have ripple effects for those hoping to follow in these very lucrative footsteps. 

This article is from The Spark, MIT Technology Review’s weekly climate newsletter. To receive it in your inbox every Wednesday, sign up here

The AI Hype Index: AI gets booed in graduation season

It is one thing to say AI will change the world. It is another to expect the class of 2026 to applaud it. In fact, when former Google CEO Eric Schmidt told University of Arizona graduates that their task is to help shape AI, he was met with a resounding chorus of boos. “I can hear you,” he said, before conceding that fears about disappearing jobs and a broken future were “rational.”

This is not exactly the message one hopes to hear while sweating under a polyester gown and tallying student loan payments. Graduates have been jeering at AI pep talks at other commencements too, including ceremonies at the University of Central Florida and Middle Tennessee State University. Still, increasingly loud skepticism hasn’t stopped OpenAI from winning court cases, raising enormous sums of money, and launching new partnerships. And AI is even earning some unlikely cheerleaders: Reese Witherspoon has warned women to embrace it or be replaced by it.

STAT+: Experimental hepatitis B treatment was a ‘functional cure’ for nearly 1 in 5, new data show

An experimental medicine helped vanquish hepatitis B in clinical trials in nearly 1 in 5 people with chronic infections caused by the virus, far outperforming available treatment options in an illness that kills 1 million people every year. 

Some 250 million to 300 million people globally have chronic hepatitis B infections, which can cause serious issues including cirrhosis and liver cancer. Current treatments, known as nucleoside analogues, lead to so-called functional cures in only 1% to 3% of patients.

But in a pair of Phase 3 trials, GSK’s bepirovirsen, or “bepi,” helped 20% and 19% of patients achieve functional cures, with no patients on placebo reaching that point, according to data released Thursday. 

Continue to STAT+ to read the full story…

STAT+: Trump’s drug-pricing deals set to be tested by new product launches

WASHINGTON — The public is about to get its first look at the prices of drugs launched since President Trump struck his most-favored-nation deals with 17 drugmakers.

Briefly, those deals require companies to launch new drugs in the U.S. at net prices roughly equal to those in other wealthy nations, though the precise terms are secret. Three prescription medicines that are set to launch in the coming months will provide the most public view yet of the practical impacts of Trump’s dealmaking.

The drugs are Baxfendy for hypertension from AstraZeneca, the insulin Awiqli from Novo Nordisk, and Veppanu, a cancer drug developed by Arvinas and Pfizer that’s set to be licensed to Rigel Pharmaceuticals. Baxfendy and Veppanu aren’t yet available in other wealthy countries that are used as comparisons for reference pricing.

Continue to STAT+ to read the full story…